Assessing ovarian status, including ovarian reserve and ovarian responsiveness, as part of an evaluation for infertility and assisted reproduction protocols
Assessment of menopausal status, including premature ovarian failure
Evaluation of infants with ambiguous genitalia and other intersex conditions
Evaluating testicular function in infants and children
Monitoring patients with antimullerian hormone-secreting ovarian granulosa cell tumors
Specimen Type
Serum
Specimen Requirements
Preferred: Serum Gel
Acceptable: Red Top
Minimum Sample Volume
0.75 mL
Stability
Refrigerated (preferred): 7 days
Frozen: 180 days
Ambient: 7 days
Unacceptable Specimen Conditions
Gross hemolysis: acceptable to 1000 mg/dL
Gross icterus: acceptable to 66 mg/dL
Limitations
Interference was observed at biotin concentrations above 30 ng/mL. Samples should not be taken from patients receiving therapy with high biotin doses until at least 12 hours following the last biotin administration.
The following drugs may interfere with this test: Cetrotide, Ovitrelle, Endometrin and Follistatin: do not use this test to analyze samples from patients who have received 1 or more of these products within 1 to 2 weeks of testing.
There is no high-dose hook effect at AMH concentrations up to 1400 ng/mL.
In rare cases, interference due to extremely high titers of antibodies to analyte-specific antibodies, streptavidin or ruthenium can occur. The laboratory should be alerted if the result does not correlate with the clinical presentation.
For diagnostic purposes, the results should always be assessed in conjunction with the patient’s medical history, clinical examination and other findings.
AMH immunoassays are not standardized and values obtained with different assay methods or kits may be different and cannot be used interchangeably.
If using as a tumor marker, test results cannot be interpreted as absolute evidence for the presence or absence of malignant disease.
